Approved Research Proposals

The table provides details of approved research proposals that have signed Data Use Agreements.

Data Request IDLead InvestigatorInstitutionResearch Proposal TitleData Contributors
3244Vojtech HuserNational Library of Medicine/NIHIdentification of Research Common Data Elements in HIV/AIDS using data science methods AbbVie, Pfizer
3246Dawn FarrellInstitute of Technology Tralee​Cochrane Review: Interventions for fatigue in inflammatory bowel diseaseAbbVie
3270Mirjana Stanic BenicUniversity Hospital Centre Rijeka​The impact of biological interventions on health‐related quality of life in adults with Crohn's diseaseAbbVie, Biogen
3287Robert AlexanderTakedaIdentification of biomarkers associated with specific sleep variablesGSK
3288Marc-Antoine SparfelTours Hospital MIDRA: influence of demographic and environmental factors on anti-tumor necrosis factor efficacy in rheumatoid arthritis a systematic review and meta-analysis of randomized controlled trialsAbbVie, Pfizer, UCB
3320John FrewRockefeller UniversityAnalysis of Outcome Measures in Hidradenitis SuppurativaAbbVie
3321Ewa OlechIQVIA Study of entry variables to optimize lupus trial designGSK
3328Klaus GottliebEli Lilly USAMapping of components of the complete blood count and comprehensive metabolic profile to disease-specific clinical and endoscopy endpoints in phase 2 and 3 clinical trials of ulcerative colitis and Crohn’s diseaseTakeda
3361Gustav NilsonneKarolinska InstitutetDistribution of interleukin -6 in human plasma implications for statistical modelling and meta-analysis AbbVie, GSK
3369Michael Ward
NIHPredicting Treatment Response to Tumor Necrosis Factor Inhibitors in Patients with Ankylosing SpondylitisAbbVie, Pfizer
3762Lin WangJohns Hopkins HospitalThe relative efficacy and safety of apalutamide, enzalutamide, abiraterone, and darolutamide for nonmetastatic castration-resistant prostate cancer
Pfizer, Project Data Sphere
3876Changyu ShenBeth Israel Deaconess Medical CenterRisk and Benefit Stratification of Treatment Effects in Patients with Atrial Fibrillation Boehringer Ingelheim, Daiichi Sankyo
4036Akira KimataUniversity of TsukubaOptimal interruption time of dabigatran per OS to Ablation (O-A time) in patients with atrial fibrillation Integrated analysis of 2 randomized controlled clinical trialsBoehringer Ingelheim
4037Karl PeaceGeorgia Southern UniversityAssessment of Matching Methods for Causal Analysis
Boehringer Ingelheim
4039Claire DaienCHU lapeyronie The most appropriate conventional DMARD to combine with tofacitinib in Rheumatoid Arthritis post hoc analysis of ORAL sync study Pfizer
4041Vivek RudrapatnaUniversity of California, San FranciscoEnhancing inference from real-world data using externally-derived missing data models: a pilot study of Ulcerative ColitisAbbVie, Johnson & Johnson, Takeda
4043Janneke van der WoudeErasmus Medical Center Effect of treatment on lipid profiles in patients with inflammatory bowel disease a systematic review and meta-analysis Pfizer
4047Miriam Oron
Skintelligence ltd.Test the prospects of expending the Skintelligence algorithm for predicting response to treatment with Alefacept and Ustekinumab in psoriatic patients affected with type I diabetesImmPort
4112Florian NaudetCHU RennesTolerability of duloxetine in the elderly and in adults: a systematic review and individual patient data meta-analysis of randomized controlled trials versus placeboAbbVie, Lilly, Lundbeck, Pfizer, Takeda
4113Lesley InkerTufts Medical CenterChronic Kidney Disease Epidemiology – Clinical Trials Consortium (CKD-EPI CT)GSK, Takeda
4115Amir MahabadiUniversity Hospital Essen, West German Heart and Vascular Center Impact of statin therapy on coronary artery calcification volume and density - A meta-analysis of randomized controlled trialsPfizer
4116Sharon StraussSt. Michael’s HospitalComparative safety and effectiveness of cognitive enhancers for Alzheimer's dementia a systematic review and individual patient data network meta-analysisAbbVie
4117John FrewRockefeller UniversityPredictors of Treatment Response, Adverse Events, Changes in Anaemia status and Assessment of Lesion Count Variability in Hidradenitis SuppurativaAbbVie
4118J. David SpenceWestern UniversityOn-Treatment analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial
4120Merryn VoyseyUniversity of Oxford The immunogenicity and sero-efficacy of pneumococcal vaccinesPfizer
4121Frederikus KlokLeiden University Medical CenterPerformance of the AF-adapted VTE-BLEED score for predicting major bleeding in patients with atrial fibrillation a post-hoc analysis of the ENGAGE-AF TIMI-48 Study Daiichi Sankyo
4275Lisa StampUniversity of OtagoSerum urate as a biomarker in gout Protocol for individual patient data analysis for OMERACT 2020
4278Jennifer QuintImperial College London Withdrawing inhaled corticosteroid (ICS) treatment in people with COPD a real world study
Boehringer Ingelheim
4316Martin OkunFort HealthCareGeospatial and Seasonal Variation in Psoriasis Severity Analysis of Placebo Response Data from Phase 3 placebo-controlled trials in moderate-severe psoriasis AbbVie
4319Maria Alice FranzoiJules Bordet InstitutClinical implications of body mass index and weight in metastatic breast cancer patients receiving abemaciclib. A combined individual patient level data sub-analysis of MONARCH 2 and MONARCH 3 trials.Lilly
4324Peng XieChongqing Medical UniversityComparative efficacy and tolerability of new-generation antidepressants for major depressive disorder in children and adolescents: protocol of an individual patient data meta-analysGSK, Lilly, Pfizer
4326John MarkmanUniversity of Rochester Phenotypic Characterization of Chronic Neuropathic Pain Following Post-Traumatic and Post-Surgical InjuryPfizer
4327Michael SzarekSUNY Downstate Medical CenterAnalysis of Total Events and Hospitalizations in the SPARCL Study Pfizer
4329, 4048Shomron Ben-HorinSun Yatsen 1st affiliated HospitalEfficacy of biologic drugs in short-duration versus long-duration inflammatory bowel diseaseAbbVie, Biogen, Johnson & Johnson, Takeda, UCB
4330Laure GossecSorbonne UniversitéDomains of health important for Rheumatoid Arthritis patients can be assessed separately: Reliability and Responsiveness of the Rheumatoid Arthritis Impact of Disease Score - 7 items (RAID.7i)Pfizer
4352Stefano BarcoUniversity Medical Center MainzDifferential effects of long-term treatment with warfarin vs. edoxaban on blood count parameters. A parallel posthoc analysis of the Hokusai VTE and Engage AF-TIMI-48 trialsDaiichi Sankyo
4540Chris GaleUniversity of LeedsEfficacy and safety of edoxaban versus warfarin in patients with atrial fibrillation and frailty insights from the ENGAGE AF-TIMI 48 trialDaiichi Sankyo
4541C Elizabeth CaldonGarvan Institute of Medical ResearchTherapeutic targeting of dual CDK4/6 inhibitor and endocrine resistant breast cancerPfizer
4913Susan HalabiDuke University Surrogate Endpoints of Overall Survival in Non-Metastatic Renal Clear Cell Carcinoma Pfizer, Project Data Sphere
4915Rachel TomkoMedical University of South CarolinaPredicting Individuals' Probability of Response to Smoking Cessation Pharmacotherapy Pfizer
4917Andrea CiprianiUniversity of Oxford Choosing the Right Antidepressant for Depressive Disorder in Adults: Individual Patient Data Network Meta-AnalysisGSK, Lilly, Lundbeck
4918Nina HilkensRadboudmc NijmegenAssociation between blood pressure, blood pressure variability and the risk of post-stroke dementiaBoehringer Ingelheim
4919Hendrik Jan GuchelaarLeiden University Medical Center (LUMC)Effect of digoxin on survival outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitorsPfizer
4920Gustavo TureckiDouglas Mental Health University InstitutePredicting Treatment Efficacy in Individuals with Major Depression -- Deep Neural Networks for Physiological Patient Parameters
4921Tim BrümmendorfUniversity Hospital Aachen Entropy based Biomarkers for individualized response on Bosutinib treatment in chronic phase CML Pfizer
4922, 3274Diane van der WoudeLeiden University Medical Center​Effect of rheumatoid factor and anticitrullinated peptide antibody on the efficacy of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritisAbbVie, Pfizer
4926Eva-Maria GamperMedical University InnsbruckComparison of the EORTC QLU-C10D with generic utility instruments and development of a comprehensive manual for its useBoehringer Ingelheim
4931Siddharth SinghUniversity of California, San DiegoEarly changes in inflammatory biomarkers and long-term outcomes in patients with IBD: A pooled post-hoc analyses of clinical trialsAbbVie, Takeda
4933Hongxia WangShanghai Jiao Tong University School of Medicine Novel predictive biomarker for therapeutic sensitivity of CKD4/6 inhibitor in breast cancer patients Pfizer
4949, 3190Vivek RudrapatnaUniversity of California San FranciscoEfficacy of Crohn’s Disease Treatment Stratified by Disease PhenotypeAbbVie, Biogen, Johnson & Johnson, Takeda, UCB
4950John “Devin” PeipertNorthwestern University Justification of PROMIS (FACIT) Fatigue Short Form 10a scale for FDA Drug Development ToolQualification in Rheumatoid Arthritis AbbVie
5073Philip RobinsonUniversity of QueenslandAssessment of treatment outcome using ASAS40 with etanercept in non-radiographic axSpA by baseline CRP - a re-analysis of trial dataPfizer
5074Sebastian ZundlerUniversity Hospital ErlangenEvaluation of the relationship between vedolizumab peripheral blood serum level at week 6 and binary clinical outcomes at week 10/14 - a meta-analysisTakeda
5079Maureen DubreuilBoston UniversityClinical and MRI predictors of Clinical Response in Axial SpondyloarthritisAbbVie
5080Joel SkaistisBeaumont Health Benefit of Anticoagulation in Cryptogenic Stroke According to Biomarker LevelBoehringer Ingelheim
5086Junko TakeshitaUniversity of PennsylvaniaA Systematic Review to Describe the Demographic Diversity of Dermatologic Clinical Trial Participants for Common Dermatologic DiseasesAbbVie, Lilly, Regeneron
5095Mathilde NijkeuterUniversity Medical Center UtrechtAssessing bleeding risk in patients with cancer-associated thrombosis Daiichi Sankyo
5096Joo Sang LeeSamsung Medical Center, South KoreaHarnessing genetic interactions to advance precision cancer medicineTempus Labs, Inc.
5098Christopher BaethgeUniversity of Cologne Medical School Dose-response relationships in antidepressant pharmacotherapy of depressive disorders with (S)SNRI: a systematic review and meta-analysisLilly
5099Jorge HernandoVall d ́Hebron University Hospital Impact of gender on multikinase inhibitors (MKIs) toxicity in patients (pts) with advanced pancreatic and gastrointestinal neuroendocrine tumors (NETs)Pfizer
5163Susan BatesColumbia University Medical CenterAssessing the tumor growth and decay rates in patients with pancreatic cancer treated with Gemcitabine/Abraxane: Comparing real world data with clinical trial dataCelgene Corporation
5165Byeongzu GhangJeju National University HospitalReanalysis of CARES study to investigate the incidence of cardiovascular events and death after initiation and discontinuation of allopurinol and febuxostat
5166Thomas MetkusJohns Hopkins University School of Medicine Severe sepsis in the cardiac intensive care unit: management strategies and outcomesLilly
5207Fasihul KhanUniversity of NottinghamA systematic review and individual patient data meta-analysis of physiological biomarkers in idiopathic pulmonary fibrosisBioLINCC, Boehringer Ingelheim, Johnson & Johnson, Roche
5209Bruce PerkinsUniversity of TorontoTRIAL-INFORMED DKA MITIGATION EDUCATIONAL TOOLBoehringer Ingelheim
5276Yan LuoKyoto UniversityPredicting the Treatment Response of Certolizumab for Individual Patients with Rheumatoid Arthritis: An Individual Participant Data Meta-Analysis UCB
5290Ashley HopkinsFlinders UniversityPredictors of therapeutic and adverse effects of medicines used in the treatment of gastrointestinal cancersBoehringer Ingelheim, GSK, Lilly, Roche
5291Sarah NevittUniversity of LiverpoolAntiepileptic drug monotherapy for epilepsy: an updated Cochrane review and individual participant data network meta-analysisUCB
5292Désirée van der HeijdeLeiden University Medical CenterMeasurement properties of the instruments used in the outcome assessment of axial spondyloarthritisUCB
5294Daniel CaldeiraUniversity of Lisbon/CCUL The clinical impact of dabigratran in patients with non-valvular atrial fibrillation who had a fall or head injury: a retrospective analysis of RE-LY Boehringer Ingelheim
5325, 5324Daniel GoldenholzBeth Israel Deaconess Medical Center Retrospective analysis of placebo arm data in clinical epilepsy trialsGSK, UCB
5330Laura BonnettUniversity of LiverpoolModelling seizure rates rather than time to an event within clinical trials of antiepileptic drugsUCB
5352Elena MyasoedovaMayo ClinicIndividualized Prediction of Treatment Response to Methotrexate in Patients with Rheumatoid Arthritis: A Machine Learning Approach
Roche, UCB
5435Matthew GilbertUniversity of VermontEffect of Albiglutide on Cardiovascular Outcomes in Older Adults with Type 2 Diabetes: a Post Hoc Analysis of a Randomized Controlled TrialGSK
5436Adrian WaggUniversity of AlbertaA pooled analysis of the efficacy and tolerability of tolterodine for the treatment of Overactive Bladder (OAB) in patients over the age of 65 years of agePfizer
5456Ramona Belfiore-OshanCritical Path Institute Validation of a Model-based Clinical Trial Simulation Tool to Optimize Clinical Trial Design of Studies to Investigate Efficacy of Potential Therapies for Duchenne Muscular Dystrophy CureDuchenne
5483David McAllisterUniversity of GlasgowAssessing heterogeneity in relative treatment efficacy by age, sex and comorbidity.Boehringer Ingelheim, Lilly, Roche, Takeda, UCB
5567Neeraj NarulaMcMaster UniversityImpact of Ulcer Size and Extent of Inflammation On Ability To Achieve Endoscopic Healing In Crohns Disease: An EXTEND Post-Hoc AnalysisAbbVie
5812Yougen WuThe Fifth People's Hospital of Shanghai, Fudan UniversityDevelopment and validation of nomograms for predicting efficacy and toxicity in cancer patients treated with immune checkpoint inhibitorsRoche
5813Phillip GarfinSeattle Genetics Inc.Effectiveness of cytotoxic chemotherapy for the treatment metastatic breast cancer subtypesRoche
5852Marliese AlexanderPeter MacCallum Cancer Centre Infective outcomes in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: an individual patient data meta-analysisRoche
5853Florian NaudetCHU RennesData-sharing and re-analysis for main studies assessed by the European Medicines Agency - a cross-sectional study on European Public Assessment ReportsAbbVie
5869Alexandra FreemanUniversity of CambridgeMeta-analysis of the adverse effects of trastuzumab in women with breast cancerRoche
5871Nobuhisa KanaharaChiba University Center for Forensic Mental Health Determination of dopamine supersensitivity psychosis in randomized controlled studies of long-acting injectable vs. oral agents of the same atypical antipsychotic in schizophrenia subjects Lilly
5872Yaw NyameUniversity of Washington Medical CenterRepresentation of Low-Grade Prostate Cancer in Metastatic Prostate Cancer TrialsPfizer
5880Benjamin SchneiderIowa State UniversityOptimal Scheduling of First-Line Therapeutics in Non-Small Cell Lung CancerLilly, Roche
5894Takashi SozuTokyo University of ScienceMatrix Decomposition in Meta-Analysis for Extraction of Adverse Event Pattern and Patient-Level Safety ProfileLilly
5897John PeipertNorthwestern UniversityJustification of PROMIS (FACIT) Fatigue Short Form 10a scale for FDA Drug Development Tool Qualification in Rheumatoid ArthritisPfizer
5901Junhao HuChinese Academy of Science Vessel pericytes NO-sGC signaling in COVID-19Hannover Medical School
5902Thrasyvoulos TzellosNorland University HospitalDevelopment and validation of a IHS4 dichotomous outcome for assessing anti-inflammatory treatment efficacy for the treatment of hidradenitis suppurativaAbbVie
5904Saskia MiddeldorpAmsterdam UMCHokusai post VTE study: long-term outcome after heparin plus edoxaban versus heparin plus vitamin K antagonists for acute deep vein thrombosis and pulmonary embolismDaiichi Sankyo
5921Paul SchulzUniversity of Texas Health Science CenterIdentification of biomarkers associated with Alzheimer’s disease progression that correlate with responses to medicationsLilly
5924Iris SommerUniversity Medical Center GroningenMeta-analysis of efficacy of cholinesterase inhibitors on individual neuropsychiatric symptoms in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodiesAbbVie, GSK, Johnson & Johnson
5925Min Hwan KimYonsei University College of MedicineAnalysis of neutrophil to lymphocyte ratio (NLR) in ER+ breast cancer patients to predict palbociclib clinical responsePfizer
5930Youssef ZeidanAmerican University of Beirut Medical CenterEvaluation of Radiotherapy Boost in Women with HER-2 positive Breast CancerRoche
5931Youssef ZeidanAmerican University of Beirut Medical CenterEvaluation of Radiotherapy in Triple Negative Breast Cancer: Analysis of the BEATRICE trial Roche
5933, 5208Ahmad AbuhelwaUniversity of South AustraliaPredictors of exposure, therapeutic and adverse effects of certolizumab pegol and baricitinib used in the treatment of rheumatoid arthritisLilly, Roche, UCB
5935Jian-Guo Zhou
The Second Affiliated Hospital of Zunyi Medical University Longitudinal peripheral blood markers as dynamic predictors to identify efficacy and safety of patients treated with immune checkpoint inhibitors (ICIs)Roche
5940Aziz MezliniMassachusetts General HospitalA novel statistical approach to detect the efficacy of drugs that have heterogeneous treatment effectsAbbVie, Boehringer Ingelheim, GSK, Johnson & Johnson, Lundbeck, Roche, Takeda, UCB
5944Pietro SpitaliLeiden University Medical CenterPrediction of disease progression in Duchenne muscular dystrophyCureDuchenne
5945Neeraj NarulaMcMaster UniversityPredictors of Mucosal Healing in Ulcerative Colitis: A Post-hoc Analysis of VARSITYTakeda
5948Georgia SalantiUniversity of BernMaking real world predictions for clinical outcomes in Relapsing-Remitting Multiple SclerosisBiogen
5950Shirley WangBrigham and Women's HospitalUnderstanding effectiveness of new drugs in older adults shortly after market entryBoehringer Ingelheim
5951, 4543Mathilde NijkeuterUMC UtrechtIndividualized prediction of recurrence risk reduction and risk of bleeding with extended anticoagulation in patients with venous thromboembolismBoehringer Ingelheim, Daiichi Sankyo
5959John DennisUniversity of Exeter Medical SchoolStratification of SGLT2 inhibitor glucose lowering therapy in Type 2 diabetesBoehringer Ingelheim, Takeda
5960Matt LinnikHannover Medical SchoolCovid-19 Pulmonary Gene Expression AnalysisLilly
5963Elyse KatzUSSAMMDA A secondary Data-Analysis to determine treatment effectiveness in Post-Traumatic Stress DisorderLilly
5968Mehul PatelKing's College Hospital NHS Foundation TrustMethods for Staging disease activity In ulcerative colitis; A comparison of endoscopy and Histology (MESIAH)Johnson & Johnson, Takeda
5974Robert SchoeversUniversity of GroningenPrescriber effects on outcome of psychopharmacological treatment of Major Depressive Disorder (MDD)Lilly
5981Mark PetersonVertex Pharmaceuticals Identifying and quantifying predictors of disease progression in common measures of physical function among boys with Duchenne Muscular Dystrophy (DMD) CureDuchenne, Lilly
5982Matthew BakerStanford UniversityInvestigating the effects of rituximab on specific cell subsets and cytokine levels in systemic lupus erythematosus patients and constructing a prediction model of treatment responseRoche
5984David BakerQueen Mary University of LondonExploring possibilities to improve the riskbenefit balance through anlaysis of the ocrelizumab phase II extension studyRoche
5985, 5327Jose Antonio Pereira da SilvaUniversidade de Coimbra, PortugalLong-term predictive value of patient global assessment regarding radiographic damage and physical function in patients with Rheumatoid Arthritis: individual patient data meta-analysisAbbVie, Pfizer, Roche, UCB
5987Glen HazlewoodUniversity of CalgaryDisease‐modifying anti‐rheumatic drugs for rheumatoid arthritis: A network meta-analysis incorporating individual patient dataAbbVie, Johnson & Johnson, Lilly, Pfizer, Roche, UCB
5988Elad SharonNational Cancer InstituteThe Role of Targeted Agents and Their Effects on Lymphocytes and Patient OutcomesRoche
5989Alexandre BetourneCritical Path InstituteSharing of Progressive Supranuclear Palsy (PSP) data with the Rare Disease Cures Accelerator - Data and Analytics Platform for Analysis of Outcome Measures and Other PurposesAbbVie
5990Yan LuoKyoto UniversityPredicting the Treatment Response of Biologics for Individual Patients with Rheumatoid Arthritis: An Individual Participant Data Meta-AnalysisAbbVie, Roche
6003Andrea QuattroneMagna Graecia University of Catanzaro Evaluation of disease progression rate in progressive supranuclear palsy using MRI biomarkers: new implications for clinical trials AbbVie
6004Lily LimUniversity of ManitobaIdentifying Trajectories of Disease Activity States in Juvenile Idiopathic Arthritis (JIA) Early After Treatment: Shortening Time to Decision to Change TreatmentRoche
6006Nicholas WhiteMahidol UniversityA Multiple-Dose Study to Assess the Effects of Azithromycin plus Chloroquine on Electrocardiograms in Healthy Subjects - COVID-19Pfizer
6007Judith GoldsteinJohns Hopkins School of MedicineNational Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) Calibrations for Low Vision Patients with age-related macular degeneration (AMD)Roche
6008David HsiehUniversity of Texas Southwestern Medical CenterPatterns of outcomes and the relevance surrogate endpoints in patients treated with immune checkpoint inhibitors.Roche
6024Cosima LocherUniversity Hospital Zurich Predictors of placebo response in opioid trials for patients with Chronic Primary Pain – An Individual-Patient Data (IPD) Meta-Analysis
6041Neeraj NarulaHamilton Health SciencesHistologic Predictors of Endoscopic Healing in Crohn's DiseaseAbbVie
6050Paul CinciripiniUT MD Anderson Cancer CenterSafety and efficacy of smoking cessation treatments in smokers with and without depressionPfizer
6062Alex MeiselUniversity Hospital of Zurich Neutrophils, Neutrophil-to-Lymphocyte Ratio (NLR) and Neutropenia as Predictors of Treatment Efficacy of Atezolizumab Monotherapy and Atezolizumab-Chemotherapy-CombinationsRoche
6063Wiesje van der FlierAmsterdam UMC, VUmcOptimizing Trial design to Achieve Personalized prevention of Alzheimer’s diseaseBoehringer Ingelheim, GSK, Johnson & Johnson, Lilly
6064Neeraj NarulaHamilton Health Sciences Comparative Effectiveness of Vedolizumab vs. Infliximab in Ulcerative Colitis Johnson & Johnson, Takeda
6068Youssef ZeidanAmerican University of Beirut Medical CenterEvaluation of Cardiotoxicity in HER-2 Positive Breast Cancer Patients Treated with Radiation Therapy and TrastuzumabyRoche
6104Pratik SinhaWashington UniversityHeterogeneous treatment effects in molecular phenotypes of sepsisLilly
6115David McAllisterUniversity of GlasgowReal-world treatment effectiveness of novel anti-diabetic agents in people with type 2 diabetes: Maximising the applicability of clinical trialsAstraZeneca, Boehringer Ingelheim, GSK, Lilly, Takeda
6118Roxana MehranIcahn School of Medicine at Mount SinaiAntithrombotic therapy in patients with atrial fibrillation after percutaneous coronary intervention: a systematic review and individual patient data network meta-analysis.Boehringer Ingelheim, Daiichi Sankyo
6464Michael WieseUniversity of South AustraliaIndividualisation of gout flare prophylaxis when initiating urate-lowering therapyTakeda
6471Floris BoschUniversity of Amsterdam Academic Medical CenterRisk of recurrent venous thromboembolism and bleeding in cancer patients an individual patient data meta-analysisPfizer
6472Soong June BaeYonsei University Health SystemImpact of neutrophil to lymphocyte ratio on prognosis in patients with HER2-positive breast cancer regarding the HER2-targeted therapyRoche
6475Tobias PolakErasmus Medical CenterCombining data from expanded access programs and conventional clinical trials: a statistical application to vemurafenibRoche
6477Tobias PolakErasmus Medical CenterTositumomab: statistical modeling of expanded access programs and conventional trialsGSK
6482Andreas MonschUniversity of Basel Analyses of available cognitive data from 200 healthy, German-speaking individuals to be used to examine potential patients
6483Bharati KumarUniversity of BathEvaluation of available statistical methods performance under non-proportional hazardsAstraZeneca, Lilly
6484Ari RosenbergUniversity of ChicagoDeveloping predictive and prognostic Artificial Intelligent (AI) digital biomarkers for soft tissue sarcomaLilly
6488Feng SunPeking UniversityAn individual participant data meta-analysis to evaluate a new category of hypoglycemic drugs (SGLT-2Is) on type 2 diabetes mellitus patient sub-groupsBoehringer Ingelheim, Johnson & Johnson
6489Line UhrenholtAalborg University Hospital Tapering strategies of biological and targeted synthetic disease-modifying antirheumatic drugs for patients with inflammatory arthritis: a systematic review of randomised controlled trials AbbVie
6494Maria Alice FranzoiJules Bordet InstituteImplications of body mass index on the biological and clinical effects of endocrine therapy and abemaciclib in the neoadjuvant settingLilly
6495, 5485Günter HöglingerHanover Medical SchoolApplication of improved statistical methodologies for clinical trials in Progressive Supranuclear PalsyAbbVie
6496Neeraj NarulaHamilton Health SciencesEndoscopic Disease Severity and Patient Reported Outcomes in Crohns DiseaseAbbVie, Johnson & Johnson
6498Timo UphausUniversity Medical Center Mainz Identifying patients with unknown stroke etiology who may benefit from a blood thining medication with Dabigatran by a clinically based scoring systemBoehringer Ingelheim
6499, 5323, 5289Ashley HopkinsFlinders UniversityPredictors of therapeutic and adverse effects of medicines used in the treatment of breast cancerAstraZeneca, Boehringer Ingelheim, Lilly, Pfizer, Roche
6515Leire LeacheNavarre Health ServiceCochrane Systematic Review Pharmacotherapy for hypertension induced left ventricular hypertrophyBoehringer Ingelheim
6520Thomas SchnitzerNorthwestern UniversityDevelopment of model to predict pain response in clinical trials of chronic pain conditionsPfizer
6521Ethan AltUniversity of North Carolina at Chapel HillBayesian probability of success for multivariate generalized linear modelsBiogen
6532Odelia CooperCedars-Sinai Medical CenterA study of how growth hormone treatment affects health outcomes in patients with noncancerous craniopharyngioma tumorsLilly
6534Diego TosiInstitut du Cancer de MontpellierAnalysis of breast cancer molecular adaptation to drugs in order to predict relapse after curative treatmentLilly
6541Dipak KotechaUniversity of BirminghamBig data and meta-analytic approaches for better phenotyping in atrial fibrillation and heart failureBoehringer Ingelheim
6543Andreas MeidHeidelberg University HospitalReproducible Machine Learning (ML) for Tumor Growth Inhibition (TGI) - can ML methods support the validity of conventional TGI metrics?Roche
6544Angela WuUniversity of OxfordInvestigating the association between smoking cessation and mental health in people with and without psychiatric disordersPfizer
6550James BrorsonThe University of ChicagoExamination of survivor functions from SOCRATES and THALES trials for kinetics of stroke recurrenceAstraZeneca
6551Siddharth SinghUniversity of California San DiegoPredicting the short- and long-term risk of serious infections in patients with Crohn’s disease: Analysis of the PYRAMID RegistryAbbVie
6593Matthieu RoustitGrenoble Alpes University HospitalExploration of regional heterogeneity in trials assessing the efficacy of recent non-insulin glucose lowering drugs on cardiovascular outcomesAstraZeneca
6594Manju SubramanianBoston Medical CenterThe Impact of Race on Short Term Treatment Response to Intravitreal anti-Vascular Endothelial Growth Factor in Diabetic Macular Edema: A Pooled AnalysisRoche
6601Dan TurnerShaare Zedek Medical CenterAdaptation and validation of the Mucosal Inflammation Non-invasive (MINI) Index for Crohn's disease in adults using the SERENE clinical trial dataAbbVie
6629Jian-Guo ZhouThe Second Affiliated Hospital of Zunyi Medical UniversityLongitudinal peripheral blood markers as dynamic predictors to identify efficacy and safety of non–small-cell lung cancer (NSCLC) patients treated with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)AstraZeneca, Lilly, Roche
6632Luca ValerioUniversity Medical Center of the Johannes Gutenberg-University MainzHealthcare resource utilization and economic burden related to pulmonary embolism. An analysis of the PREFER in venous thromboembolism (VTE) studyDaiichi Sankyo
6633Luca ValerioUniversity Medical Center MainzPerformance status and long-term clinical outcomes in pulmonary embolism patients with cancer. An analysis of Hokusai VTE Cancer studyDaiichi Sankyo
6641Anna FeeneyMassachusetts General HospitalAntidepressants in children and adolescents with Major Depressive Disorder and the influence of placebo response: a meta-analysisPfizer
6642Neeraj NarulaHamilton Health SciencesModified Multiplier SES-CD (MM-SES-CD) on Predicting Endoscopic Remission in Crohns DiseaseAbbVie, Johnson & Johnson, Takeda
6686Neeraj NarulaHamilton Health SciencesExtended Validation of an Ulcerative Colitis Vedolizumab Decision Support ToolTakeda
6710Gus SlotmanInspira Health NetworkIdentifying Patients in the PROWESS SHOCK Clinical Trial Among Whom Drotrecogin Alfa (DrottAA) Reduced MortalityLilly
6712Yeon-Mok OhAsan Medical CenterDevelopment and validation of a prediction model for the indication of inhaled corticosteroid (ICS) in patients with chronic obstructive pulmonary disease (COPD)GSK
6716Nigam ShahStanford UniversityApplying machine learning tools to personalize dabigatran treatment decisionsBoehringer Ingelheim
6732Yung-Chuan HuangFu Jen Catholic University HospitalDecision Tree Model for Dose Selection of Dabigatran in Non-valvular Atrial Fibrillation PatientsBoehringer Ingelheim
6734Andreas SuhrbierQIMR Berghofer Medical Research instituteThe K18 mouse model recapitulates the transcriptomic response to acute COVID-19 Acute Respiratory Distress syndrome (ARDS) in humansHannover Medical School
6739Rifaquat RahmanDana Farber Cancer InstituteEvaluation of Differences in Trial and Non-Trial Patients and Leveraging of External Data for More Efficient Clinical Trial Designs in Newly Diagnosed GlioblastomaProject Data Sphere, Roche
6740Georgios PaliourasNational Centre for Scientific Research 'Demokritos' (NCSR-D)in-silico DMD: Developing computational predictive models for the progression of Duchenne Muscular DystrophyCureDuchenne
6758Qian ChenHubei Cancer HospitalRetrospective analysis of the effect of first-line bevacizumab treatment on survival and prognosis of patients with advanced non-small cell lung cancer treated with second-line immunotherapyRoche
6759, 5936Zhi XiaoXiangya Hospital, Central-South UniversityRoles of neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapyRoche
6764Camila Olarte ParraLondon School of Hygiene and Tropical MedicineHypothetical estimand in clinical trials: an application of causal inference and missing data methodsAstraZeneca
6765Dan HanleyJohns Hopkins UniversityPandemic response COVID-19 Research Collaboration PlatformNYU Grossman School of Medicine, Intermountain Healthcare, Washington University School of Medicine, Bassett Research Institute, The Queen's Medical Center, Duke University, University Medical Center New Orleans
6836Alana RojewskiMedical University of South CarolinaSmoking Cessation Pharmacotherapy Efficacy in Comorbid Medical Populations: Secondary Analysis of the EAGLES Randomized Clinical TrialPfizer
6860Nicholas LangeColumbia UniversityBelatacept in obese kidney transplant recipientsBristol Myers Squibb
6866Andy LimMonash UniversityMeta-analysis of early stroke recurrence rate in minor strokeAstraZeneca
6869Zhen LinRobot Bacon CorporationEvaluating Clinical Trial Data Conventions for the Observational Medical Outcomes Partnership Common Data Model (OMOP CDM)AstraZeneca, Ferox Therapeutics, GSK, Roche, Takeda
6881, 5484Stefan LeuchtTechnical University of MunichIndividual-patient-data (IPD) meta-analysis of the efficacy of clozapine versus second-generation antipsychotic drugs in patients with treatment-resistant schizophreniaLilly, Pfizer
7070Georgios TsakonasKarolinska InstitutetAnaplastic Lymphoma Kinase- Brain Prognostic Index (ALK-BPI) a novel prognostic score for brain metastasized ALK+ Non Small Cell Lung Cancer (NSCLC)Roche
7072James SignorovitchAnalysis GroupDevelopment of natural history controls to contextualize clinical trial outcomes of boys with Duchenne muscular dystrophy treated with DS-5141BCureDuchenne
7074Gregory YH LipUniversity of LiverpoolImpact of atrial fibrillation and the effects of comorbidities and treatment on disease progression and outcomesBoehringer Ingelheim
7076Elias ErikssonUniversity of GothenburgPost hoc patient-level analysis of the impact of amitriptyline, selective serotonin reuptake inhibitors, and placebo of individual items of the Hamilton Depression Rating ScaleGSK
7077Neeraj NarulaHamilton Health SciencesDominant Patient Reported Outcomes on Predicting Mucosal Healing in Crohns DiseaseAbbVie, Johnson & Johnson
7078Alberto Martini
San Raffaele UniversityRole of body mass index and Beta Blockers in metastatic urothelial carcinomaRoche
7101Jason LukeUniversity of PittsburghAnalysis of gene expression profiles in melanoma tumors exhibiting differential lactate dehydrogenase biomarker levels and correlation with immunotherapy responseBristol Myers Squibb
7104Jakob NäslundUniversity of GothenburgItem-level effects of adjuvant olanzapine and/or olanzapine monotherapy in treatment-resistant depressionLilly
7126Alessio CortelliniImperial College LondonThe predictive role of inflammation indices in patients treated with immunotherapy or chemotherapy for advanced non-small cell lung cancer.Roche
7127Alexa KimballBeth Israel Deaconess Medical CenterEffects of adalimumab on inflammation-associated abnormal hematologic patterns in patients with Hidradenitis SuppurativaAbbVie
7136Shou-Ching TANGUniversity of Mississippi Medical Center (UMMC) Cancer Center and Research Inst.Validation of trastuzumab-emtansine (T-DM1) Toxicity Score to predict response to T-DM1 treatment in metastatic breast cancerRoche
7140Michael J. SorichFlinders University of South AustraliaEarly markers of clinical outcome to ipilimumab therapy for advanced melanomaBristol Myers Squibb
7142Sara TedeschiBrigham and Women’s HospitalCausal inference cohort re-analysis of the 'CARES' trial to better understand the roles of colchicine, allopurinol, and febuxostat on cardiovascular events among patients with goutTakeda
7143Chaim SingalexperiMindThe effects of systemic anti-infective concomitant medications on progression of neurological diseasesBoehringer Ingelheim, GSK, Lilly, UCB
7144Timothy PerkAIQ SolutionsExternal validation of the AIQ predictive score of clinical benefit using Sodium Fluoride (NaF) position emission tomography/computed tomography (PET/CT) images in metastatic prostate cancer (mPC)Pfizer
7145Joan BusnerSignant HealthPsychometric evaluation of Positive and Negative Syndrome Scale (PANSS) in adolescent schizophrenia trialsOtsuka
7147Carmela TartagliaUniversity of TorontoExploring the heterogeneity of cognitive profile in patients with Progressive Supranuclear Palsy (PSP) enrolled in the ABBV-8E12 trial and the relationship to brain volumesAbbVie
7156Angelina TjokrowidjajaUniversity of SydneyConcordance between disease progression by Cancer Antigen 125 and computerized tomography (CT) progression in patients with relapsed advanced ovarian cancer treated with poly(adenosine diphosphate [ADP]–ribose) polymerase inhibitor: a pooled analysisAstraZeneca
7158Neeraj NarulaHamilton Health SciencesPatient Reported Symptoms as Predictors of Endoscopic Improvement in Ulcerative ColitisTakeda
7159, 6634James SignorovitchAnalysis Group, Inc.Associations between steroid treatment, functional outcomes and disease milestones among non-ambulatory patients with Duchenne muscular dystrophy (DMD)CureDuchenne
7161Wesley KerrUniversity of California, Los AngelesReal time monitoring of individual response to antiseizure medication treatment during clinical trialsGSK, Johnson & Johnson, UCB
7162Andrew BottomleyEuropean Organisation for Research and Treatment of Cancer (EORTC)Cancer Clinical Trials Pooling of Quality Life Data (CATAPULT) initiativeBristol Myers Squibb
7163Laura MezquitaHospital Clinic and the Translational Genomics Group at IDIBAPSProspective validation of the Lung Immune Prognostic Index in patients with non-small cell and small cell lung cancersProject Data Sphere, Roche
7164Jörg EllingerUniversity Hospital BonnEvaluation of CRP (c-reactive protein) flare phenomena as an early predictor of response to the Atezolizumab + Bevacizumab therapy in renal cell carcinomaRoche
7224Keiichi FujiwaraGynecologic Oncology Trial and Investigation Consortium (GOTIC)Early prediction of survival outcome of large-scale randomized clinical trials using artificial intelligence technologynBoehringer Ingelheim, Lilly, Roche
7225Neeraj NarulaHamilton Health SciencesEarly vs. Delayed Response to Vedolizumab in Ulcerative ColitisTakeda
7227Catrin Tudur-SmithUniversity of LiverpoolAdd-on treatment for refractory focal-onset epilepsy: Individual Participant Data Network Meta-analysisGSK, Johnson & Johnson, UCB
7232Neil OxtobyUniversity College LondonIdentification of heterogeneity in Alzheimer’s disease clinical trials using computational modellingTakeda
7233Gregory YH LipUniversity of LiverpoolEvaluating the outcomes and characterisation of atrial fibrillationBoehringer Ingelheim
7241Frederick ReimherrPsychiatric and Behavioral Solutions, LLCRetrospective Analysis of Emotional Symptoms in Adults with ADHD and Improvement Produced by BrexpiprazoleOtsuka
7243Emanual MaverakisUniversity of California DavisDeveloping Models from Existing Atopic Dermatitis Outcome DataGSK
7245Manabu TakakiOkayama UniversityClinical moderators of response to nalmefene in alcohol dependence: Results from a randomized controlled trial in Japan.Otsuka
7274Jun ChenWest China Hospital, Sichuan UniversityEfficacy comparison of biologics (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) in treatment of severe eosinophilic asthma — a network meta-analysisGSK
7277David CarterMMS HoldingsInternational COVID-19 Data Alliance COVID-19 WorkbenchRoche
7283Franziska MichorDana Farber Cancer InstituteLarge-scale public data reuse to model immunotherapy response and resistanceBristol Myers Squibb
7288Vipual JairathAlimentiv Inc.Placebo Rates in Inflammatory Bowel Disease: An Individual Patient Data Meta-analysis of Randomized Controlled TrialsAbbVie, Johnson & Johnson, Takeda
7289Gianluca RigatelliRovigo General HospitalOutcomes of Left Main Purcutaneous Coronary Intervention across age classesDuke University
7312Marianna Kruithof-de JulioUniversity of BernMachine learning for personalized drug response prediction for bladder and prostate cancer patientsTempus Labs, Inc.
7317Emanual MaverakisUniversity of California DavisDeveloping Efficacy Assessment Tools from Existing Psoriasis Clinical Trial Outcome DataLilly
7321Neeraj NarulaHamilton Health SciencesA Comparison of the Rapidity of Clinical Response between Infliximab and Tofacitinib for Ulcerative ColitisJohnson & Johnson, Pfizer
7322Zhengfei ZhuFudan University Shanghai Cancer CenterClinical value and optimal candidate of cranial radiotherapy in atezolizumab-treated advanced non-small cell lung cancer with baseline brain metastasisRoche
7323Toshifumi KishimotoNara Medical UniversityDevelopment of the optimal treatment of Nalmefene in patients with alcohol dependenceOtsuka
7325Andreas ArtemiouCardiff UniversityPredicting outcomes (death, improvement, survival) of COVID-19 patients on Standard of Care (SoC) NYU Grossman School of Medicine, Roche, University Medical Center New Orleans
7379Michele RomoliBufalini HospitalAntithrombotics in patent formane ovale (PFO)-related stroke: a meta-analysis stratified for the risk of paradoxical embolism score (RoPE)Boehringer Ingelheim
7381Tomoya HirotaUniversity of California San FranciscoEarly Prediction of Treatment Response to Antipsychotics for Irritability and Aggression in Autism Spectrum DisorderJohnson & Johnson, Otsuka
7384Ulrich MansmannLudwig-Maximilian’s University MünchenApplication of Estimands and Causal Reasoning in the Reanalysis of Endpoint Measures in Advanced/Metastatic Non-Small Cell Lung Cancer Clinical TrialsAstraZeneca, Roche, Takeda
7387Neeraj NarulaHamilton Health SciencesComparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn’s DiseaseAbbVie, Johnson & Johnson, Takeda
7388Byeongzu GhangJeju National University HospitalReanalysis of CARES study to investigate the changes of estimated glomerular filtration rate after long-term febuxostat or allopurinol treatment in gout patientsTakeda
7394, 6117, 5895Ashley HopkinsFlinders UniversityPredictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancersRoche
7395Xiaoling ShangShandong UniversitySurvival analysis of advanced lung adenocarcinoma harboring epidermal growth factor receptor gene mutation receiving the combination treatment of atezolizumab, Bevacizumab,carboplatin and PaclitaxelRoche
7396Mary Ann LukasGSKModeling and Simulation of ambrisentan pharmacokinetics in young childrenDuke University School of Medicine
7399 Yoichi NaitoNational Cancer Center Hospital EastCorrelation of doxorubicin dose and survival in patients with soft tissue sarcoma; Data from two studies (a larger phase III study and a smaller phase II study) will be combined and analyzed.Lilly
7400Aryelly RodriguezThe University of EdinburghWhat are the re-identification risk scores of publicly available anonymised clinical trial datasets?GSK, UCB
7404Reena KhannaLawson Health Research InstituteA Study to Assess the Correlation Between Harvey Bradshaw Index and Patient Reported Outcome 2 in Crohn's Disease Patients Enrolled in Large Scale Randomized Controlled TrialsTakeda
7414Nobuyuki HoritaYokohama City University HospitalProgression-Free Survival, Response Rate, and Disease Control Rate as Predictors of Overall Survival in Trials Evaluating Atezolizumab Regimens for Advanced, Locally Advanced, and Recurrent Non-Small Cell Lung Carcinoma: Independent-Patient-Data Analysis.Roche
7427Joachim TanMonash UniversityDose reduction and discontinuation of disease modifying anti-rheumatic drugs (DMARDs) for juvenile idiopathic arthritisAbbVie, Johnson & Johnson, Roche
7435Noah GoldfarbUniversity of MinnesotaDecision tool for the use of adalimumab for hidradenitis suppurativaAbbVie
7445Catherine ThieblemontInsermEvaluation of surrogate markers in marginal zone lymphomaRoche
7462Junjie ZhuoHainan UniversityAssociations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles with Clinical Profiles in the Progression of Alzheimer’s DiseaseAstraZeneca
7492Yang ZhaoNanjing Medical UniversityAn Investigation on the Role of Blood Biomarkers as Predictors for Individualized Treatment Regimen Selection in Non-Small Cell Lung Cancer.Roche
7493Nina HilkensRadboudumc NijmegenBlood pressure variability and progression of white matter hyperintensities after ischemic strokesBoehringer Ingelheim
7495Thomas AntalffySmart Respiratory Products LtdAnalysing Clinical Applicability of CompEx EndpointsAstraZeneca
7498Riccardo PolosaCenter of Excellence for the Acceleration of Harm Reduction (CoEHAR)A Machine Learning approach to improve smoking cessation trialsPfizer
7501Min-Gul KimJeonbuk National University HospitalCOVID-19 clinical trial data utilization to develop external control datasets in COVID-19 therapeutics developmentHCor Research Institute, Hospital Universitario Austral, Lilly, Montreal Heart Institute, Roche, University of Minnesota
7503, 6635Leslie PadrnosMayo ClinicEfficacy and safety of anticoagulants for the treatment of acute venous thromboembolism (VTE) in patients with hematologic malignancies a systematic review and individual patient level data meta-analysisBoehringer Ingelheim, Daiichi Sankyo, Pfizer
7518Lucio ManentiUniversity Hospital of ParmaRole of persistent and isolated reduced serum complement 3 (sC3) in lupus nephritisRoche
7520Malathi RamJohns Hopkins UniversityACEi/ARB medications for hospitalized patients with COVID-19 – an individual patient data (IPD) based pooled analysisBassett Medical Center, Sharp Healthcare, University of Kansas Medical Center, University of Minnesota
7535Joshua DragoMemorial Sloan Kettering Cancer CenterStatin use and clinical outcomes on ado-trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancerRoche
7539Amit EtkinAlto Neuroscience, Inc.Clinical and demographic predictors of antidepressant treatment in patients with major depressive disorder with agomelatine versus vortioxetineLundbeck
7541Amit EtkinAlto Neuroscience, IncRole of clinical, historical and demographic factors in the response to antidepressants versus placeboLilly, Takeda
7542Neeraj NarulaHamilton Health SciencesVedolizumab vs. Adalimumab in Ulcerative Colitis: Validation of Indirect ComparisonsAbbVie, Takeda
7543Margaret SalisburyVanderbilt University Medical CenterDefining the physiologic trajectory of presymptomatic through advanced pulmonary fibrosisBoehringer Ingelheim, Roche
7544Abhimanyu MahajanRush University Medical CenterSensory trick and benefit from botulinum toxin in cervical dystoniaAbbVie
7549Vipul JairathAlimentiv IncResponsiveness of the UC-100 Score in Patients with Moderately to Severely Active Ulcerative ColitisAbbVie, Johnson & Johnson, Takeda
7552Anna van EijkLiverpool School of Tropical MedicineImpact of Malaria in Pregnancy on InfantsPfizer
7581Rustam Al-Shahi SalmanUniversity of EdinburghCollaboration Of Controlled Randomised trials of Oral Antithrombotic agents after intraCranial Haemorrhage (COCROACH)Daiichi Sankyo
7583, 5932Youssef ZeidanAmerican University of Beirut Medical CenterEvaluation of Radiotherapy after Complete Response to Neoadjuvant Chemotherapy in HER-2 Positive Breast Cancer PatientsRoche
7587Sudhir SivakumaranCritical Path InstituteDevelopment of model-informed drug development tools for Alzheimer's DiseaseLilly
7590Noémie LangUniversity Hospitals of GenevaFRILLY: a retrospective single center study on Fractionated Rituximab to avoid Lysis Syndrome in Aggressive B-LymphomaProject Data Sphere, Roche
7591, 7392Neeraj NarulaHamilton Health SciencesPredictors of Placebo Response and Remission in Ulcerative Colitis and Crohn’s DiseaseAbbVie, Johnson & Johnson, Pfizer, Takeda
7595Ashley HopkinsFlinders UniversityPredicting therapeutic and adverse outcomes to immune checkpoint inhibitors used in cancer treatmentRoche
7597Junko TakeshitaUniversity of PennsylvaniaEvaluating Racial and Ethnic Differences in the Quality-of-Life Impact of Atopic DermatitisLilly, Pfizer, Regeneron
7598Harry SouthworthData Clarity Consulting LtdExploration of ailments related to back pain in the medical history data from clinical studies of healthy subjects using formal hypothesis testing and data miningAstraZeneca, GSK
7599Hwanhee HongDuke UniversityCombining data sources to identify effect moderation for personalized mental health treatmentJohnson & Johnson, Lundbeck, Takeda
7601Guru SonpavdeAdventHealth Cancer InstituteMathematical prognostic model utilizing multi-platform dynamics in patients with metastatic urothelial carcinoma receiving post-platinum PD1/L1 inhibitorsRoche
7606Amber SalterUniversity of Texas Southwestern Medical CenterComorbidity and Clinical Trials of Disease-Modifying Therapies in Multiple SclerosisRoche
7609Joao Pedro FerreiraPorto UniversityThe impact of albiglutide on heart failure outcomes among patients with type 2 diabetes with and without heart failure at baselineGSK
7620Emilie Sbidian University Paris Est Creteil (UPEC) Systemic pharmacological treatments for chronic plaque psoriasis A Systematic Review and an Individual-Patient Data Network Meta-Analysis of Randomized Controlled Trials AbbVie, Johnson & Johnson, Lilly, Pfizer, UCB
7621Adam BoxerUniversity of California San FranciscoBayesian Disease Progression Modeling and Clinical Trial Design for Progressive Supranuclear Palsy - Richardson's SyndromeAbbVie
7654Shirley YuUniversity of Sydney Update of individual data meta-analysis of intra-articular corticosteroids in knee and hip osteoarthritisSanofi
7656Neeraj NarulaHamilton Health SciencesImpact of Steroid Weaning Regimens on Outcomes in Clinical Trials of Ulcerative ColitisAbbVie, Johnson & Johnson, Pfizer, Takeda
7658Arman SabbaghiPurdue UniversityTripartite Estimands for Adherence Causal Inference in Clinical Trials, With Applications for the Development of COVID-19 TreatmentsSanofi
7660Shirley YuUniversity of SydneyPredictors of placebo response to local (intra-articular) therapy in osteoarthritis: an individual patient data meta-analysisSanofi
7661Baocheng ChangTianjin Medical UniversityEffects of Lixisenatide on the primary prevention of diabetic kidney disease in population with high riskSanofi
7662Benoit YouUniversité Claude Bernard LyonPrognostic And Predictive Value Of The Modeled PSA Kinetics Parameters In Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel Or Cabazitaxel (Phase III Trial — FIRSTANA)Sanofi
7663, 7385Amit EtkinAlto Neuroscience, Inc.Cognitive predictors of antidepressant treatment outcome in patients with major depressive disorderLilly, Lundbeck, Takeda
7667Ashley HopkinsFlinders UniversitySummarising the therapeutic and adverse effects of anticancer medicines according to race and sex: pooled analysis of clinical trials of contemporary treatments for solid tumoursAstraZeneca, Bayer, Boehringer Ingelheim, Daiichi-Sankyo, Johnson & Johnson, Lilly, Pfizer, Roche,
Sanofi, Takeda
7743Caroline QuachCHU Sainte-JustineIs there a Difference in the Immune Response, Efficacy, and Safety of Seasonal Influenza Vaccine in Males and Females? - A Meta-AnalysisSanofi
7744, 6055Florian NaudetCHU RennesInferential reproducibility of therapeutic research: a registered report for a cross-sectional study of RCTs available on major data-sharing platformsAbbVie, Boehringer Ingelheim, Lilly, Pfizer, Roche, Sanofi, Takeda, UCB
7758Nahid SultanaUniversity of SheffieldIndirect comparisons of time-to-event outcomes using single-arm studies in health technology assessment (Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma)GSK
7760John (Devin) PeipertNorthwestern UniversityStudy of Functional Assessment of Chronic Illness Therapy (FACIT) GP5 Item as a Measure of Treatment Tolerability in Advanced Cancer Patients across Multiple Tumour Sites and Treatment TypesLilly, Pfizer, Roche
7772Neeraj NarulaHamilton Health SciencesCombined Histologic and Endoscopic Endpoints in Ulcerative ColitisTakeda
7776Stefan LeuchtTechnical University of MunichAntipsychotic drugs versus placebo in the treatment of antipsychotic naïve and/or first episode children or adolescents with psychosis: A systematic review and meta-analysis of double-blind randomized controlledLilly, Otsuka
7777Paul AyukNewcastle-upon-Tyne Hospitals NHS TrustUsing Dabigatran etexilate to prevent blood clots in women after childbirthBoehringer Ingelheim
7779Luís InêsUniversity of Beira InteriorDerivation and validation of the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) severe disease activity category: post-hoc analysis of the anifrolumab clinical trials in active systemic lupus erythematosus.AstraZeneca
7782Yang LiRenmin University of ChinaA new covariate randomization method for multi-arm randomized controlled trialsGSK
7785Christian JonassonNordicRWEUsing Norwegian real world data to emulate and reproduce results from oncology clinical trialsRoche
7794Joan CarlesVall D'Hebron Institute of OncologyCo Medication (aspirin, statins and metformin) analysis in patients with metastatic Castration Resistant Prostate Cancer treated with ChemotherapySanofi
7797Jörg EllingerUniversity Hospital BonnEvaluation of the performance of the modified Glasgow prognostic score in urothelial carcinoma, non-small cell lung cancer and renal cell carcinomaPfizer, Project Data Sphere, Roche
7801, 6864Yoshie OmachiNational Center of Neurology and PsychiatryElucidation of the predictive factors for active and placebo drug response on social functioning and quality of life (QOL) in psychiatric illnesses including developmental disordersJohnson & Johnson, Lilly, Shionogi
7804Qingyun LiGenecast Biotechnology Co., LtdAn exploratory study of the fusion co-mutated immune microenvironment in Non-small cell lung cancerRoche
7807Hayato NiiyamaYokohama City UniversityA Post-hoc Analysis using Secondary Data of Clinical Trial from M14-033 Study to Evaluate Average Treatment Effect and Heterogeneous Treatment Effect of Adalimumab in Maintenance Phase for Patients with Ulcerative ColitisAbbVie
7809David James PinatoImperial College, LondonThe predictive role of concomitant antibiotics in patients treated with immunotherapy or oral treatment for unresectable hepatocellular carcinoma (HCC)Roche
7810Diego ChowellIcahn School of Medicine at Mount SinaiMachine learning model to predict cancer immunotherapy responseRoche
7817Neeraj NarulaHamilton Health SciencesPredictors of Histologic Response using Antibodies Against Interleukin-5 in Eosinophilic EsophagitisGSK
7818Werner WeitschiesUniversity of GreifswaldDevelopment and improvement of an in vitro tool, which simulates the physiological characteristics of the ascending colonSanofi
7819Jeanine Roeters van LennepErasmus University Medical CenterEfficacy & Safety of Proprotein Convertase Subtilisin/Kexin type 9 Inhibitors: a Systematic Review and Meta-analysis of Real-World DataSanofi
7822Linbin Luthe 900th Hospital of PLATrajectories of alpha-fetoprotein and liver cancer outcomes after atezolizumab treatmentRoche
7823Marc CarrierUniversity of OttawaAnticoagulation for the Prevention of Arterial Thrombosis in Ambulatory Patients with Cancer: A Systematic Review GSK, Sanofi
7824Feng SunPeking UniversityAn individual participant data meta-analysis to evaluate PD1 vs PD-L1 Inhibitors in Asian subgroup Cancer patientsDaiichi Sankyo, Roche
7826Carl TuressonLund UniversityEfficacy and safety of tumor necrosis factor inhibitors (TNFi) in seronegative rheumatoid arthritis patients who are inadequate responders to conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs). A systematic literature review with meta-analysis.AbbVie, Johnson & Johnson, Lilly, UCB
7828Ramiro SofiaLeiden University Medical CenterSPondyloarthritis EARly Definition (ASAS-SPEAR) Analysis of Symptom Duration Thresholds Using Pooled Data from Randomized Controlled TrialsAbbVie, Johnson & Johnson, Lilly, Pfizer, UCB
7830Yi-Wen TsaiNational Yang Ming Chiao Tung UniversityCost effectiveness analysis of atezolizumab plus chemotherapy for untreated extensive stage small cell lung cancer in AsiaRoche
7835Hiroyuki KusuharaUniversity of TokyoAssessment of the drug-drug interactions risks of drugs based on the clinical data of the plasma biomarkersAbbVie
7840Marco TagliamentoIRCCS Ospedale Policlinico San MartinoClinical Effect of Chemotherapy-Immunotherapy Combination in the First-Line Treatment of Older Patients with Non-Small Cell Lung CancerRoche
7842Marco TagliamentoIRCCS Ospedale Policlinico San MartinoPooled Efficacy and Safety Analysis of the Phase III Studies of Alectinib vs. Crizotinib in Untreated ALK-Positive Non-Small Cell Lung CancerRoche
7844Linong JiPeking University People's HospitalRisk stratification and responder identification for glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) in Type 2 Diabetes Mellitus (T2DM): a machine learning facilitated post-hoc analysis of clinical trialsBioLINCC, GSK, Johnson & Johnson
7845Craig NelsonUniversity of California San FranciscoChange in cognition during antidepressant treatment of late life depressionLilly, Lundbeck
7848Jennifer LundUniversity of North Carolina at Chapel HillImproving Colon Cancer Therapy Decisions by Extending Trial RepresentationSanofi
7849Linda MarchioroPaul-Ehrlich-InstitutDeterminants of study design for vaccines against opportunistic bacterial infections a proof-of-concept for data-driven, individual patient data (IPD) analyses.Sanofi
7850Vipul JairathUniversity of Western OntarioImpact of concomitant baseline medication on efficacy of biologics and small molecules for Inflammatory Bowel DiseaseAbbVie, Johnson & Johnson, Pfizer, Takeda, UCB
7854Vipul JairathUniversity of Western OntarioEfficacy of medical therapies for ulcerative colitis according to disease distribution: An individual patient data meta-analysis of randomized controlled trialsAbbVie, Johnson & Johnson, Pfizer, Takeda
7856Evandro de AzambujaInstitut Jules BordetMetastatic HER2-positive breast cancer treated with docetaxel, trastuzumab, and pertuzumab: the impact of early response on patient survivalRoche
7857Rentao Yu Chongqing Medical UniversityCutaneous adverse effects of immunotherapy medications in the treatment of cancers and their associations with overall survival Daiichi Sankyo, Roche
7858Jie ZhaXiamen UniversityRetrospective cohort study with internal and external validation of a predictive tool for progression of disease within 2 years (POD24) risk assessment in follicular lymphoma patientsRoche
7860Kemi Williams54geneDescriptive analysis of UNITY Global study data in NigeriaCertara
7868Anne-Marie DingemansErasmus MC University Medical CenterPredictive clinical characteristics for weight gain in patients treated with alectinibRoche
7873Xue YangBeijing Cancer HospitalCrizotinib followed by alectinib vs alectinib alone: analysis of treatment-naïve patients with non-small cell lung cancer (NSCLC) harboring anaplastic lymphoma kinase (ALK) -rearrangementRoche
7874Chiara Alessandra CellaIstituto Europeo di OncologiaAddressing the synergistic effect of metformin in patients with Pancreatic neuroendocrine tumors treated with sunitinib: a post-hoc analysis from the main pivotal trials.Pfizer
7875Marco ValgimigliCardiocentro Ticino, Lugano and Universita della Svizzera ltaliana (USI)P2Y12 inhibitor or Aspirin moNoTHERapy as secondary prevention in patients with coronary artery disease: in individual patient data meta-analysis (PANTHER collaborative initiative)Sanofi
7882 José González-Gomariz Fundacion para la Investigacion Medica Aplicada (FIMA) Study of the expression of several cytokines related with the survival of advanced melanoma patientsBristol Myers Squibb
8052Wataru FukuokayaThe Jikei University School of MedicineAssociation of serum magnesium levels with effectiveness of atezolizumab in advanced urothelial carcinomaRoche
8056Ashley HopkinsFlinders UniversitySummarising the therapeutic and adverse effects of antibody-drug conjugates in older women with breast cancer: A review of clinical trial individual-participant dataRoche
8175Guoxing WanHubei University of MedicineEfficacy and safety of atezolizumab plus bevacizumab for patients with advanced hepatocellular carcinoma based on albumin-bilirubin gradeRoche
8180Sheng LuoDuke UniversityClinical and molecular characteristics of human epidermal growth factor receptor 2-positive and human epidermal growth factor receptor 2-negative breast cancerDaiichi Sankyo, Lilly, Pfizer, Roche
8236Gao-Jun TengZhongda Hospital, Southeast UniversityThe role of prior transarterial chemoembolization in atezolizumab plus bevacizumab in hepatocellular carcinomaRoche
8244Frank DoyleRoyal College of Surgeons IrelandDo psychometrics matter? The effects of advanced psychometric analyses on depression randomised trial outcomesGSK, Lilly, Pfizer, Takeda
8263George NtaiosUniversity of ThesalyRisk of myocardial infarction in patients with paroxysmal vs. non-paroxysmal atrial fibrillation: an individual patient data meta-analysis of the ENGAGE-AF and RE-LY trialsBoehringer Ingelheim, Daiichi Sankyo
8266Shenghong ZhangThe first affiliated hospital of Sun Yat-sen UniversityThe prognostic value of faecal calprotectin for long-term outcomes in ulcerative colitisTakeda
8287Damian J. RalserUniversity Hospital BonnEvaluation of the easy-to-implement modified Glasgow prognostic score (mGPS) in patients with previously treated human epidermal growth factor receptor 2-positive advanced breast cancer in the KATE2 clinical trialRoche
8294Neeraj NarulaHamilton Health SciencesExtended Validation of an Ulcerative Colitis Vedolizumab Decision Support Tool for Outcome Prediction with TofacitinibPfizer
8316Vipul JairathAlimentivCorrelation Between Symptoms and Objective Measures of Disease Activity in Patients with Moderate to Severe Ulcerative Colitis and Crohn’s DiseaseAbbVie, Johnson & Johnson, Pfizer, Takeda
8324 Jeroen Dekervel Universitaire Ziekenhuizen LeuvenResponse Evaluation Criteria in Solid Tumors (RECIST) vs modified RECIST response durability in advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab Roche
8325Xiaodan TangNorthwestern UniversityDoes scoring method impact estimation of significant individual changes using Patient-Reported Outcomes Measurement Information System (PROMIS) measures? Comparing Classical Test Theory versus Item Response TheoryAbbVie
8327Eva HosterLudwig-Maximilian University MunichConstructing estimands for overall survival within causal frame work for dynamic treatment schemes in oncology: Simulation and a clinical trial exampleRoche
8344Xiaoling ShangShandong UniversityA clinical variable based-Nomogram could predict survival for Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and EtoposideRoche
8347Hong Jae ChonCHA Bundang Medical CenterThyroid immune-related adverse events correlated with favorable clinical outcome in patients with advanced hepatocellular carcinoma treated with atezolizumab and bevacizumabRoche
8349Nqoba TsabedzeUniversity of WitwatersrandThe efficacy of beta-blockers on morbidity and mortality endpoints in black hypertensive patients: A meta-analysisGSK
8377Neeraj NarulaHamilton Health ServicesEstimating Differences in the Comparison of Outcomes in Clinical Trials for Ulcerative Colitis Patients using Patient-Level Data and Aggregated Data Network Meta-AnalysisAbbVie, Johnson & Johnson, Pfizer, Takeda
8427Ahmad AbuhelwaUniversity of SharjahPredictors of exposure, therapeutic and adverse effects of medicines used in the treatment of multiple myelomaJohnson & Johnson, Sanofi, Takeda
8435Hui ZhengChengdu University of Traditional Chinese MedicinePredictors of galcanezumab in the preventive treatment of migraineLilly
8436David SchadeNM Non profit Society to Prevent Symptomatic Heart DiseaseDevelopment of an Atherosclerosis Reversal CalculatorAstraZeneca
8438Sheng LuoDuke UniversityDevelopment of novel statistical methods to detect treatment effect in Alzheimer’s disease clinical trials over timeAbbVie
8440David SeiffgeInsel Gruppe AGAndexanet alfa and the risk of haematoma expansion in patients with non-traumatic intracerebral haemorrhage – a pooled individual patient data analysis of ANNEXA-4 ICH and TICH-NOAC AstraZeneca
8445Kelley KidwellUniversity of MichiganUse of external control with longitudinal data for drug evaluation in Duchenne muscular dystrophy a Bayesian small sample, sequential, multiple assignment randomized trial design (snSMART)CureDuchenne, Lilly
8446, 7479, 7075Elias ErikssonUniversity of GothenburgEfficacy of serotonin reuptake inhibitors in children and adolescentsAbbVie, GSK, Lilly, Lundbeck, Pfizer
8450Dennis McGonagleUniversity of LeedsThe effect of Body Mass Index (BMI) and Age on Baricitinib efficacy in Covid-19 patientsLilly
8542João Sérgio NevesFaculty of Medicine of University of PortoAlbiglutide and Cardiovascular Outcomes in Type 2 Diabetes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition UseGSK
8557Fan GeGuangzhou Medical UniversityOrgan-specific metastatic landscape dissects programmed death ligand-1 (PD-L1) blockade efficacy in advanced cancerLilly, Roche
8558Pablo Guisado VascoHospital Universitario Quironsalud MadridInvestigating the impact of antibodies against SARS-CoV-2 on the effectiveness of interleukin-6 inhibitors in Covid-19 patientsRoche
8559Dag AarslandKing’s College LondonPredicting Cognitive Abilities and Treatment Outcome of Major Depressive Disorder in Elderly Patients Using Vortioxetine and Duloxetine AntidepressantsLundbeck
8563Kenta YoshidaGenentech, Inc.Tumor Growth Inhibition-Overall Survival (TGI-OS) model development and validation for hormone receptor positive (HR+)human epidermal growth factor receptor 2 negative (HER2-) breast cancerPfizer
8564SANGWOO KIMYonsei University Health SystemDevelopment of Immune Phenotype-specific Immune Checkpoint Inhibitor Response (anti-programmed death ligand-1) Prediction AlgorithmBristol Myers Squibb
8585Daniel Schachter UnigranrioEfficacy of Calcitonin gene-related peptide (CGRP) monoclonal antibodies for medication overuse headache in chronic migraine patients A systematic review and meta-analysis Lilly, Lundbeck
8588Wenlong ZhongSun Yat-sen Memorial Hospital of Sun Yat-sen University (SYSU)The influence of antibiotics on survival outcomes for bladder cancer patients being treated with immune checkpoint inhibitor therapyRoche
8593Hyon ChoiMassachusetts General HospitalSerum urate reduction, gout flares, and risk of major cardiovascular events during urate-lowering therapy initiation target trial emulation and self-controlled case series analysisTakeda
8603Wencai Jiang Chengdu Second People's Hospital Predictive value of high‐sensitivity cardiac troponin‐T for Major Adverse Cardiovascular Events in patients with Chronic coronary heart disease GSK
8606Daria IgudesmanAdventHealth Translational Research InstituteEvaluating the association of eating window duration and timing of calorie distribution with glycemic parameters and body weightJaeb Center for Health Research Foundation, Inc.
8609Fredrik SchjesvoldOslo University HospitalPersonalized prediction of progression-free survival in multiple myeloma patients treated with isatuximab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone only, using combined machine learning and mechanistic modeling.Sanofi
8699Niklas KlümperUniversity Hospital BonnEvaluation of baseline and on-treatment serum biomarkers to predict immunotherapy response in solid cancers Roche
8700Leo BuckleyBrigham and Women's HospitalColchicine Adverse Effects Research in people with Covid-19 randomized to colchicine treatmentMontreal Heart Institute
8720George NtaiosUniversity of ThessalyAssociation between statin treatment and cardiovascular outcomes in patients with atrial fibrillation Boehringer Ingelheim, Daiichi Sankyo
8751Diederik DippelErasmus MC University Medical CenterPrediction of the treatment benefit of intravenous alteplase treatment for acute ischemic stroke Boehringer Ingelheim
8753 Issa Dahabreh Harvard T.H. Chan School of Public Health Dabigatran versus Warfarin in Patients with Atrial Fibrillation Extending inference from the RE-LY trial to real world target population Boehringer Ingelheim
8756Eyal DassauEli Lilly and CompanyAssessment of insulin utilization and insulin delivery metrics in people with type 1 diabetes mellitus using blood glucose excursions, combined with nutrition and exercise information from the T1-DEXI datasetJaeb Center for Health Research Foundation, Inc.
8757Sandra Tessa HattenhauerUniversity Hospital Bonn Baseline immune signature score as predictor for response to atezolizumabbevacizumab in hepatocellular carcinoma Roche
8758Michael SzarekCPC Clinical ResearchComparison of RGX-202-01 with ramucirumab or aflibercept in the treatment of patients with recurrent colorectal cancer harboring a RAS mutation Lilly, Sanofi
8775Shenghong ZhangThe first affiliated hospital of Sun Yat-sen University Predictors for therapeutic outcomes in patients of ulcerative colitis receiving Janus kinase inhibitors Galapagos, Pfizer
8806Timothy Gaulton Massachusetts General Hospital Understanding the impact of body mass index on the effectiveness of baricitinib as a treatment for individuals hospitalized with COVID-19 Lilly, NIAID (a data-sharing platform funded by the National Institutes of Health)
8809Jing YuSichuan UniversityConstructing a predictive model for lung cancer immunotherapy Tempus Labs, Inc.
8893Eleonora ManzoniUniversity of PadovaDetection and prediction of physical activity in type 1 diabetic subjects.Jaeb Center for Health Research Foundation, Inc.